Streetbeat News

Price Targets

EL

Telsey Advisory Group has maintained its 'Outperform' rating on Estee Lauder Cos (NYSE:EL) but has lowered the price target from $250 to $210.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:13 am

WMT

Telsey Advisory Group analyst Joseph Feldman has reiterated an 'Outperform' rating on Walmart (NYSE:WMT) and maintained a price target of $185.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:12 am

DLTR

Telsey Advisory Group analyst Joseph Feldman has reiterated an 'Outperform' rating on Dollar Tree (NASDAQ:DLTR) and maintained a price target of $162.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:10 am

QSR

JP Morgan analyst John Ivankoe has initiated coverage on Restaurant Brands Intl (NYSE:QSR) with an Overweight rating and a price target of $82.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:09 am

STRC

Jefferies analyst Stephen Volkmann has downgraded Sarcos Technology (NASDAQ:STRC) from Buy to Hold and lowered the price target from $4.25 to $1.15.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:07 am

PODD

Baird analyst Jeff Johnson has downgraded Insulet (NASDAQ:PODD) from Outperform to Neutral and lowered the price target from $320 to $219.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:05 am

GOLF

Jefferies analyst Randal Konik has upgraded Acushnet Hldgs (NYSE:GOLF) from Hold to Buy and raised the price target from $61 to $84.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 8:55 am

CCOI

Goldman Sachs analyst Brett Feldman has upgraded Cogent Comms Hldgs (NASDAQ:CCOI) from Sell to Neutral and raised the price target from $43 to $64.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 8:45 am

NVDA

Keybanc analyst John Vinh maintains an Overweight rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $550 to $620.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 8:17 am

WST

Keybanc analyst Paul Knight maintains an Overweight rating on West Pharmaceutical Servs (NYSE:WST) and raises the price target from $385 to $415.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 8:12 am